相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
Benjamin P. Levy et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2019)
Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
Qing Zhang et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2019)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L) 1 Therapy
M. Hellmann et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy
David Briere et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
G. L. Uy et al.
LEUKEMIA (2017)
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier et al.
ESMO OPEN (2017)
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Ashley Orillion et al.
CLINICAL CANCER RESEARCH (2017)
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng et al.
CLINICAL CANCER RESEARCH (2016)
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives
Insa Schiffmann et al.
EPIGENETICS (2016)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
Kiavash Movahedi et al.
CANCER RESEARCH (2010)
Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS
Maria A. Halili et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
分享论文
